How drugs move
desire, arousal & climax
A working source of truth on how illicit substances and prescription medications reshape human sexual function. Every entry is read across six phases and marked by which way it pushes and how strong the evidence is. Most drugs don't simply help or hurt — they split the phases, lifting one while flattening another.
Drug × phase matrix
Search or filter, then click any row for mechanism, pharmacokinetics, sex differences, reversibility and sources. Click a phase header to sort by its effect.
How to read a cell: the glyph shows which way the drug pushes that phase; the row's tier dot shows how strong the evidence is. Click any row for the full picture.
| Substance / medication | ||||||
|---|---|---|---|---|---|---|
Alcohol CNS depressant | Biphasic: Low-dose disinhibition raises psychological desire; expectancy effects are large. | Biphasic: Disinhibits subjective arousal at low dose; suppresses physiological genital response as BAC rises. | Inhibitory: Suppresses penile tumescence above low doses; chronic use drives erectile dysfunction. | Inhibitory: Increases ejaculatory latency; impairs orgasmic capacity at higher doses. | Biphasic: Disinhibition and relaxation give way to sedation and numbing as dose climbs. | Inhibitory: High doses fragment encoding; blackout at extreme intoxication. |
Cannabis (THC) Cannabinoid | Biphasic: Low doses may raise desire; high or chronic use suppresses it. | Mixed: Variable; sensory enhancement for some, blunting for others. | Biphasic: High or chronic use associated with erectile difficulty. | Mixed: Low doses reported as permissive for orgasm, particularly in women. | Facilitatory: Heightened sensory and tactile experience commonly reported. | Inhibitory: Acute impairment of encoding and short-term recall. |
Cocaine Stimulant | Facilitatory: Acute dopamine surge and disinhibition sharply raise desire. | Mixed: Subjective arousal up, but vasoconstriction undercuts genital response. | Inhibitory: Vasoconstriction impairs erection; rare priapism reported. | Inhibitory: Delayed ejaculation and anorgasmia are common. | Facilitatory: Intense acute euphoria and confidence. | Mixed: Variable; heavy intoxication degrades encoding. |
Amphetamine / Methamphetamine Stimulant | Facilitatory: Strongly increased; compulsive hypersexuality via mesolimbic dopamine. | Biphasic: Heightened early; erratic at high dose or with chronic use. | Inhibitory: High-dose vasoconstriction impairs erection ('crystal dick'). | Inhibitory: Orgasm and ejaculation markedly delayed. | Facilitatory: Prolonged, intense, high-stamina encounters reported. | Mixed: Variable; sleep deprivation and intoxication degrade recall. |
MDMA / empathogens Entactogen | Facilitatory: Increased in more than 90% of users. | Mixed: Subjective arousal up; erection impaired in ~40% of men. | Inhibitory: Erectile impairment common despite heightened desire. | Inhibitory: Orgasm delayed but frequently perceived as more intense. | Facilitatory: Profound emotional intimacy and satisfaction; sometimes without desire for penetrative sex. | Mixed: Emotionally vivid encoding; fine detail variable. |
Opioids (heroin, fentanyl, methadone) Mu-opioid agonist | Inhibitory: Chronic use sharply reduces libido via androgen deficiency. | Inhibitory: Suppressed arousal and genital response with sustained use. | Inhibitory: Erectile dysfunction is common on maintenance therapy. | Biphasic: Single doses may delay ejaculation; chronic use causes anorgasmia. | Biphasic: Acute euphoric 'rush' vs chronic anhedonia and blunting. | Mixed: Sedation degrades encoding at higher doses. |
Ketamine Dissociative (NMDA antagonist) | Mixed: Reduces aversion and can facilitate in chemsex settings; not a true desire booster. | Inhibitory: RCTs show diminished subjective arousal intensity. | Inhibitory: Dissociation impairs coordination and physical performance. | Insufficient: Little direct evidence on orgasmic effect. | Mixed: Dissociation reshapes the experience; facilitates some acts, alienates others. | Inhibitory: Anterograde impairment; state-dependent encoding. |
GHB / GBL GABA-B agonist | Facilitatory: Disinhibition raises desire and lowers sexual restraint. | Facilitatory: Subjective enhancement of touch and sensuality. | Biphasic: Facilitatory at low dose; sedation abolishes performance as dose rises. | Mixed: Reports vary; sedation can blunt orgasm. | Facilitatory: Euphoric, tactile, disinhibited — the reported draw of the drug. | Inhibitory: Sedative doses impair encoding. |
Poppers (alkyl nitrites)caution Nitric-oxide donor | Neutral: Little direct effect on desire beyond disinhibition. | Facilitatory: Intense brief rush and disinhibition. | Mixed: Smooth-muscle relaxation eases penetration, but hypotension can undermine erection. | Facilitatory: Reported intensification of orgasm. | Facilitatory: Brief, intense sensory rush. | Neutral: No notable memory effect at typical use. |
Psychedelics (LSD, psilocybin) 5-HT2A agonist | Mixed: Variable and set/setting dependent. | Mixed: Heightened sensory awareness, but altered consciousness can intrude. | Inhibitory: Acute performance often impaired during the experience. | Mixed: Reports range from intensified to inaccessible. | Facilitatory: Emotional connection and intensity frequently reported; occasionally disruptive. | Mixed: Vivid but distorted encoding of the experience. |
Nicotine / tobacco Vasoconstrictor | Neutral: Minimal direct effect on libido. | Inhibitory: Reduced genital blood flow blunts arousal. | Inhibitory: Vasoconstriction and endothelial dysfunction impair erection. | Neutral: No consistent direct orgasmic effect. | Neutral: No notable subjective sexual effect. | Neutral: Not a memory factor in this context. |
SSRIs / SNRIs Serotonergic antidepressant | Inhibitory: Reduced libido is a hallmark effect. | Inhibitory: Impaired arousal and genital response. | Inhibitory: Erectile dysfunction and genital anesthesia. | Inhibitory: Delayed or absent orgasm; used deliberately for premature ejaculation. | Inhibitory: Emotional and sensory blunting of the experience. | Neutral: Not a primary memory effect. |
Post-SSRI sexual dysfunction (PSSD)caution Persistent syndrome | Inhibitory: Persistent loss of libido after discontinuation. | Inhibitory: Persistent impaired arousal and genital anesthesia. | Inhibitory: Persistent erectile dysfunction reported. | Inhibitory: Orgasmic and ejaculatory anhedonia. | Inhibitory: Emotional blunting may persist alongside sexual symptoms. | Insufficient: Not a defining feature. |
Bupropion NDRI antidepressant | Facilitatory: Improves desire via dopaminergic and noradrenergic tone. | Facilitatory: Generally arousal-preserving or enhancing. | Facilitatory: Low rate of erectile side effects; can improve function. | Facilitatory: Preserves or improves orgasmic capacity. | Facilitatory: Less blunting than serotonergic antidepressants. | Neutral: Not a memory factor. |
Trazodonecaution SARI antidepressant | Mixed: Variable; generally less suppressive than SSRIs. | Facilitatory: Low-dose pro-erectile effect reported historically. | Biphasic: Pro-erectile at low dose but carries priapism risk. | Mixed: Less orgasmic impairment than SSRIs. | Neutral: Sedation is the main subjective effect. | Neutral: Not a memory factor. |
Antipsychotics (prolactin-raising) D2 antagonist | Inhibitory: Hyperprolactinemia and D2 blockade lower libido. | Inhibitory: Impaired arousal and genital response. | Inhibitory: Erectile and ejaculatory impairment via alpha-blockade. | Inhibitory: Anorgasmia and ejaculatory dysfunction. | Inhibitory: Reward blunting reduces subjective quality. | Neutral: Not a primary memory effect. |
Aripiprazole (prolactin-sparing) D2 partial agonist | Neutral: Largely libido-sparing; can restore desire when switched from a prolactin-raising agent. | Neutral: Generally preserved. | Neutral: Lower erectile impairment than typical antipsychotics. | Neutral: Orgasmic function largely preserved. | Neutral: Less reward blunting than high-D2-blockade agents. | Neutral: Not a memory factor. |
Benzodiazepines GABA-A modulator | Inhibitory: Reduced libido at typical doses; a minority report the opposite. | Inhibitory: CNS depression blunts arousal. | Inhibitory: Impaired erection via enhanced GABA-A tone. | Inhibitory: Dose-dependent delayed orgasm or anorgasmia. | Mixed: Anxiety reduction can improve the experience for some. | Inhibitory: Anterograde amnesia at higher doses. |
Beta-blockers & thiazides Antihypertensive | Inhibitory: Older beta-blockers lower testosterone and desire. | Inhibitory: Reduced pelvic blood flow blunts arousal. | Inhibitory: Thiazides and older beta-blockers raise erectile-dysfunction rates. | Neutral: No consistent direct orgasmic effect. | Inhibitory: Central sedation can dampen the experience. | Neutral: Not a memory factor. |
Finasteride / 5-ARIscaution 5-alpha-reductase inhibitor | Inhibitory: Decreased libido during use; may persist in PFS. | Inhibitory: Reduced arousal and penile sensation. | Inhibitory: Erectile dysfunction; possible cavernosal changes. | Inhibitory: Reduced ejaculate volume. | Inhibitory: Anhedonia and emotional blunting in PFS. | Inhibitory: Brain fog and cognitive complaints in PFS. |
Gabapentinoids α2δ calcium-channel ligand | Inhibitory: Decreased libido reported. | Inhibitory: Reduced arousal. | Inhibitory: Erectile dysfunction common in case series. | Inhibitory: Characteristic anorgasmia and ejaculatory failure. | Neutral: No prominent subjective-quality signature. | Neutral: Not a primary memory effect. |
ADHD stimulants (Rx) Prescription stimulant | Biphasic: Raised at low dose; suppressed at higher dose. | Biphasic: Dopaminergic enhancement vs noradrenergic vasoconstriction. | Biphasic: Erectile dysfunction can emerge at higher doses. | Inhibitory: Delayed orgasm/ejaculation at higher doses. | Mixed: Focus and drive vs over-stimulation. | Neutral: Not a primary memory factor here. |
PDE5 inhibitors (sildenafil, tadalafil)caution Erectile treatment | Neutral: No direct effect on desire. | Facilitatory: Enables genital arousal when sexual stimulation is present. | Facilitatory: Restores and sustains erection — the core indication. | Neutral: No direct orgasmic effect. | Facilitatory: Restored function improves the overall experience. | Neutral: Not a memory factor. |
Flibanserin (Addyi)caution Desire treatment | Facilitatory: Modest increase in desire — the target effect. | Facilitatory: Small improvement in arousal. | Neutral: Not an arousal-organ treatment. | Neutral: No direct orgasmic effect. | Facilitatory: Modest gain in satisfying events. | Neutral: Not a memory factor. |
Bremelanotide (Vyleesi) Desire treatment | Facilitatory: Central melanocortin activation raises desire. | Facilitatory: Enhances arousal circuitry centrally. | Neutral: Not primarily an erectile agent. | Neutral: No direct orgasmic effect. | Facilitatory: Improved desire and arousal experience. | Neutral: Not a memory factor. |
Testosterone / hormone therapy Androgen treatment | Facilitatory: Most reliable response — desire improves in hypogonadal patients and in women. | Facilitatory: Improved arousal across sexes. | Mixed: Erection improves modestly; least reliably tied to serum testosterone. | Facilitatory: Improved orgasm reported, notably in women. | Facilitatory: Improved pleasure and sexual self-image. | Neutral: Not a memory factor in this context. |
Dopaminergics (apomorphine, cabergoline) Off-label treatment | Facilitatory: Dopaminergic tone raises desire. | Facilitatory: Apomorphine acts on central pro-erectile pathways. | Facilitatory: Pro-erectile effect studied for erectile dysfunction. | Mixed: Variable; prolactin-lowering can restore function. | Facilitatory: Restored reward and function. | Neutral: Not a memory factor. |
Effect valence
Evidence tier
The facilitatory–inhibitory axis
Across every substance, the same neurochemical tug-of-war decides the direction of each cell.
Dopamine, melanocortins, oxytocin, NO/cGMP, testosterone
Mesolimbic reward and the hypothalamic MPOA and PVN drive motivation and genital reflexes. Nitric oxide relaxes cavernosal smooth muscle; testosterone primes the whole system. Push these and desire, arousal and erection rise.
Serotonin (5-HT2A/2C), prolactin, excess GABA & alpha-adrenergic tone
Serotonergic load blunts orgasm and erection; prolactin signals post-orgasmic satiety; heavy GABAergic or alpha-adrenergic tone shuts down genital response. Push these and the phases flatten.
One pathway, many phases
A drug can hit desire circuitry and genital circuitry in opposite directions at once — stimulants raise drive while constricting vessels; serotonergics deepen closeness while delaying climax. That dissociation is the recurring story of the matrix.
Safety & persistent syndromes
A few effects are not matters of degree. These carry the strongest cautions in the literature.
Nitrates / poppers + PDE5 inhibitors
Both converge on the nitric-oxide–cGMP pathway. Combined, they can cause catastrophic, potentially fatal hypotension. This is an absolute contraindication — the single most dangerous drug–sex interaction in the reference.
PSSD & post-finasteride syndrome
Sexual dysfunction can outlast the drug. PSSD is recognized by the EMA's pharmacovigilance committee (2019); post-finasteride syndrome is reported but mechanistically unresolved. Both warrant explicit consent before starting.
Opioid-induced androgen deficiency
Chronic opioids suppress the hypothalamic–pituitary–gonadal axis, driving low libido, erectile dysfunction and infertility in a large share of long-term users — often reversible with dose reduction, buprenorphine or testosterone therapy.
Method & evidence tiers
Evidence here is not uniform, and the matrix marks the difference on every row. Clinical and mechanistic data are strongest for antidepressants, antipsychotics, PDE5 inhibitors, hormones and antihypertensives. Much illicit-drug phenomenology rests on smaller studies, surveys and harm-reduction reports — a genuinely weaker tier, shown as such. Where clinical measurement and lived accounts diverge (MDMA and cannabis as reported “aphrodisiacs” versus measured performance impairment), both are kept in view.
This is a reference, not medical advice. It synthesizes published pharmacology for a general and professional readership. Individual care depends on a clinician who knows the specific person. Contested syndromes are labeled as recognized-but-unresolved rather than settled fact.